Navigation Links
Soligenix Reports Third Quarter 2009 Financial Results
Date:11/13/2009

her J. Schaber, PhD, President and CEO of Soligenix. "With the initiation of our confirmatory Phase 3 clinical trial of orBec® in acute GI GVHD, orBec® is poised to potentially be the first FDA approved therapy for this unmet medical need. Additionally, Soligenix received significant new grant funding for its biodefense and radiation enteritis programs, as well as new equity financing and a $1 million milestone payment from our North American partner Sigma-Tau. We are looking forward to completing a productive 2009 and continuing that positive momentum in 2010."

Soligenix's revenues, which primarily relate to receipts from NIH grants, for the third quarter of 2009 were approximately $767,000 compared to $606,000 for the third quarter of 2008. Revenues for the first nine months of 2009 were approximately $1.6 million compared to $1.8 million for the first nine months of 2008.

Soligenix's net loss for the third quarter of 2009 was approximately $1.7 million, or $0.01 per share, compared to $0.5 million, or $0.005 per share, for the third quarter of 2008. The net loss for the first nine months of 2009 was approximately $5.6 million, or $0.03 per share, compared to $3.1 million, or $0.03 per share, for the first nine months of 2008. These larger net losses were primarily attributed to increased research and development (R&D) spending in connection with the preparation and initiation of the confirmatory Phase 3 clinical trial of orBec® for the treatment of GI GVHD.

R&D expenses for the third quarter of 2009 were approximately $1.1 million, compared to $60,000 for the third quarter of 2008. R&D expenses for the first nine months of 2009 were approximately $3.8 million, compared to $1.4 million for the first nine months of 2008.

General and administrative (G&A) expenses for the third quarter of 2009 were approximately $618,000, compared to $410,000 for the third quarter of 2008. G&A ex
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Proove ... at the International Spine Intervention Society’ s 23rd Annual Scientific Meeting ... 1st, 2015. With a focus on evidence-based research and clinical application, the event ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) ... humor and excellent customer service. Images such as the Fonz in a lab coat ... some flavor to the humdrum spectroscopy field. , FireflySci is proud to be ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
(Date:8/27/2015)... Aug. 27, 2015 HUYA Bioscience International (HUYA) today ... the Japan Society of HTLV-1, held this week at ... purpose of the Society is to promote research on ... of medical technology and research related to these fields ... "HUYA is proud to support this prestigious conference," ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... Merge eFilm will acquire AccuImage Diagnostic Corp. ... $6 million cash deal announced on Wednesday. , ,Merge ... to close the deal with the San Francisco-based company ... and other specialty physicians, includes three-dimensional visualization tools that ...
... Vogel, Department of Health and Human Services; Tom Still, ... and Human Services and park warden at Arusha National ... Arusha, Tanzania Even if former Wisconsin Gov. ... administration, his legacy at the Department of Health of ...
... Wis. The biotechnology firm OpGen hopes its new CEO ... said on Monday. R.H. Joseph Shaw is the former CEO of ... comes to OpGen with a good history of raising serious funds, ... David Schwartz , one of OpGens founders and a professor ...
Cached Biology Technology:Thompson's HHS legacy will include efforts to combat disease in Africa 2Thompson's HHS legacy will include efforts to combat disease in Africa 3OpGen recruits CEO to further gene-mapping business 2
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the second ... Second quarter contract revenue of $ 85.2 million, ... margins of 26 % , Second quarter ... from royalties in the current quarter , Operating ... pleased to present another strong financial quarter, with all our divisions ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD ... to advance crypto-currencies such as Bitcoin into the consumer ... way to manage all payments.  The ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... Calif., Jan. 9, 2012 Aria Diagnostics (formerly ... publication of data supporting a directed, non-invasive approach ... for evaluation of two common fetal trisomies linked ... of Trisomy 21 (associated with Down syndrome) and ...
... on the Olympic Peninsula joined in an exceptional partnership ... of Washington to develop a set of science-based options ... and sustainability in the face of a changing climate. ... hydrology, roads, fish, and wildlife on the peninsulaare published ...
... their offspring so they inherit either their mother,s or ... offspring are more likely to have daughters. Weaker ... produce more sons. The study, by scientists at ... University (Japan), is published today (9 January) in the ...
Cached Biology News:Aria Diagnostics announces publication of first peer-reviewed data for new noninvasive prenatal test 2Partnership yields options for adapting to climate change on the Olympic Peninsula 2Fit females make more daughters, mighty males get grandsons 2
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... Molecular Probes is pleased to offer ... the ultrasensitive detection of primary amines. ... Indiana University, the ATTO-TAG reagents are ... (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all ...
... Probes is pleased to offer the ... ultrasensitive detection of primary amines. Developed ... University, the ATTO-TAG reagents are similar ... naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all of ...
...
Biology Products: